Trius Therapeutics, Inc. (TSRX)

[surf1944]

8:34AM Trius Therapeutics reports positive results from Phase 1 lung study of Torezolid Phosphate; second generation oxazolidinone antibiotic achieves high exposure in lung (TSRX) 6.24 : Co announces results from its Phase 1 clinical trial to evaluate the ability of torezolid to penetrate into the lung for potential use to treat lung infections. In the Phase 1 lung study, the exposure of torezolid in ELF was 48-fold higher than that achieved in plasma. This exposure was significantly above the minimum inhibitory concentration, for both Staphylococcus aureus and Streptococcus pneumoniae for the full daily dosing interval providing a pharmacokinetic rationale for the administration of a single 200 mg dose of torezolid phosphate every 24 hours for the treatment of lung infections caused by these pathogens. These results are consistent with those of prior animal studies that demonstrated considerable penetration of torezolid into lung fluids and tissues which translated into high efficacy in lung infections due to S. pneumoniae and S. aureus pathogens.